Acquisition by Duker Jay S. of 195000 shares of Eyepoint Pharmaceuticals subject to Rule 16b-3

EYPT Stock  USD 8.53  0.19  2.18%   
Slightly above 57% of Eyepoint Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Eyepoint Pharmaceuticals stock suggests that many investors are alarmed at this time. Eyepoint Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Eyepoint Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Eyepoint Pharmaceuticals Director, Officer: President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Eyepoint insider trading alert for acquisition of restricted stock units by Duker Jay S., Director, Officer: President And Ceo, on 3rd of January 2025. This event was filed by Eyepoint Pharmaceuticals with SEC on 2025-01-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Eyepoint Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Eyepoint Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Eyepoint Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Eyepoint Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Eyepoint Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts

Eyepoint Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Eyepoint Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Eyepoint Pharmaceuticals' options.

Eyepoint Pharmaceuticals Fundamental Analysis

We analyze Eyepoint Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Eyepoint Pharmaceuticals is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Eyepoint Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eyepoint Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Eyepoint Pharmaceuticals Related Equities

DRTSWAlpha Tau   14.29   
0%
100.0%
VIRXViracta Therapeutics   7.19   
0%
50.0%
HOOKHookipa Pharma   6.37   
0%
44.0%
CMRXChimerix   4.76   
0%
33.0%
PLXProtalix Biotherapeutics   3.80   
0%
26.0%
SLSSellas Life   2.02   
0%
14.0%
RVPHReviva Pharmaceuticals   1.06   
0%
7.0%
BMEABiomea Fusion   1.56   
10.0%
0%
CABACabaletta Bio   1.57   
10.0%
0%
DAWNDay One   2.40   
16.0%
0%
HCWBHCW Biologics   2.86   
20.0%
0%
TERNTerns Pharmaceuticals   3.02   
21.0%
0%
OBIOOrchestra BioMed   3.27   
22.0%
0%
ABOSAcumen Pharmaceuticals   4.62   
32.0%
0%
IPHAInnate Pharma   5.65   
39.0%
0%
MREOMereo BioPharma   6.13   
42.0%
0%
ALXOAlx Oncology   6.75   
47.0%
0%
XFORX4 Pharmaceuticals   7.69   
53.0%
0%

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.